目的 觀察注射用紅花黃色素在老年患者腦梗死恢復(fù)期早期的治療療效。方法 老年腦梗死恢復(fù)期早期患者（病后1～3個(gè)月）44例，隨機(jī)分為治療組和對照組各22例，治療組用注射用紅花黃色素100 mg，對照組用鹽酸川芎嗪注射液80 mg，分別加入生理鹽水250 mL中靜滴，1次/d，治療14 d，治療前后患者進(jìn)行臨床療效評分及經(jīng)顱多普勒超聲（TCD）檢查并記錄大腦前動脈、中動脈動脈收縮期最大血流速度（Vsp）及平均血流速度（Vmv）。同時(shí)，觀察治療過程中兩組患者有無不良反應(yīng)發(fā)生。結(jié)果 治療后，治療組療效評分總有效率59.09%，對照組為45.45%，兩組療效差異有顯著性（P＜0.05）。TCD檢查治療組患者責(zé)任病灶和非責(zé)任病灶側(cè)大腦中動脈Vsp及Vmv增加較對照組更為明顯（P＜0.01，P＜0.05）。兩組患者均未出現(xiàn)嚴(yán)重的不良反應(yīng)。結(jié)論 注射用紅花黃色素能通過改善患者非責(zé)任病灶側(cè)血管的血流而改善臨床癥狀，在腦梗死恢復(fù)期早期可適當(dāng)選用，同時(shí)無不良反應(yīng)發(fā)生。

Objective To observe the effect of safflower yellow for injection in treatment of elderly patients with cerebral infarction at early recovery stage. Methods Elderly patients (44 cases) with cerebral infarction at early recovery stage (suffered from the disease for 1—3 month) were randomly divided into the treatment (22 cases) and control (22 cases) groups. The patients in the treatment group were administered with safflower yellow for injection 100 mg, and the patients in the control group were administered with ligustrazine hydrochloride injection 80 mg. The above two were added into 250 mL physiological saline for iv drip, once daily for 14 d. The patients in the two groups were recorded the clinical score and accepted transcranial Doppler (TCD) sonography to check the maximum blood flow velocity (Vsp) and mean blood flow velocity (Vmv) of cerebral anterior and media arteries before and after the treatment. At the same time, adverse reaction was observed in the treatment. Results After the treatment, the efficiency of treatment and control groups was 59.09% and 45.45% with significant difference (P < 0.05). TCD examination showed that Vsp and Vmv of cerebral media arteries in duty and non-duty area were increased more than those in the control group (P < 0.01, P < 0.05). There was no serious adverse reaction in the two groups. Conclusion Safflower yellow for injection could improve the clinical symptoms of patients by changing the blood flow in non-duty area, so that it could be chosen to use for the treatment in the cerebral infarction properly at the early recovery stage with the little adverse reaction.